{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:40:21Z","timestamp":1790872821285,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81971687"],"award-info":[{"award-number":["81971687"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82001776"],"award-info":[{"award-number":["82001776"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014137","name":"Shanghai Shenkang Hospital Development Center","doi-asserted-by":"publisher","award":["SHDC2023CRD014"],"award-info":[{"award-number":["SHDC2023CRD014"]}],"id":[{"id":"10.13039\/501100014137","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Colorectal Dis"],"DOI":"10.1007\/s00384-025-05044-z","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T18:56:19Z","timestamp":1764701779000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["MRI-defined high-risk rectal cancer patients: comparison of treatment response and survival outcomes between total neoadjuvant therapy and neoadjuvant chemoradiotherapy\u2014a propensity score matched analysis"],"prefix":"10.1007","volume":"40","author":[{"given":"Ruiting","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianyu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajia","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,2]]},"reference":[{"key":"5044_CR1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.5445","volume":"8","author":"E Fokas","year":"2022","unstructured":"Fokas E, Schlenska-Lange A, Polat B et al (2022) Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for patients with locally advanced rectal cancer: long-term results of the CAO\/ARO\/AIO-12 randomized clinical trial. JAMA Oncol 8:e215445. https:\/\/doi.org\/10.1001\/jamaoncol.2021.5445","journal-title":"JAMA Oncol"},{"key":"5044_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114291","volume":"210","author":"E Fokas","year":"2024","unstructured":"Fokas E, Williams H, Diefenhardt M et al (2024) Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: pooled analysis of the CAO\/ARO\/AIO-12 and the OPRA randomized phase 2 trials. Eur J Cancer 210:114291. https:\/\/doi.org\/10.1016\/j.ejca.2024.114291","journal-title":"Eur J Cancer"},{"key":"5044_CR3","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1200\/JCO.22.00032","volume":"40","author":"J Garcia-Aguilar","year":"2022","unstructured":"Garcia-Aguilar J, Patil S, Gollub MJ et al (2022) Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy. J Clin Oncol 40:2546\u20132556. https:\/\/doi.org\/10.1200\/JCO.22.00032","journal-title":"J Clin Oncol"},{"key":"5044_CR4","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S1470-2045(15)00004-2","volume":"16","author":"J Garcia-Aguilar","year":"2015","unstructured":"Garcia-Aguilar J, Chow OS, Smith DD et al (2015) Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. Lancet Oncol 16:957\u2013966. https:\/\/doi.org\/10.1016\/S1470-2045(15)00004-2","journal-title":"Lancet Oncol"},{"key":"5044_CR5","doi-asserted-by":"publisher","first-page":"119","DOI":"10.4251\/wjgo.v13.i2.119","volume":"13","author":"M Tuta","year":"2021","unstructured":"Tuta M, Boc N, Brecelj E, Peternel M, Velenik V (2021) Total neoadjuvant therapy vs standard therapy of locally advanced rectal cancer with high-risk factors for failure. World J Gastrointest Oncol 13:119\u2013130. https:\/\/doi.org\/10.4251\/wjgo.v13.i2.119","journal-title":"World J Gastrointest Oncol"},{"key":"5044_CR6","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/S1470-2045(15)00159-X","volume":"16","author":"C R\u00f6del","year":"2015","unstructured":"R\u00f6del C, Graeven U, Fietkau R et al (2015) Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO\/ARO\/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 16:979\u2013989. https:\/\/doi.org\/10.1016\/S1470-2045(15)00159-X","journal-title":"Lancet Oncol"},{"key":"5044_CR7","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.0071","volume":"4","author":"A Cercek","year":"2018","unstructured":"Cercek A, Roxburgh CSD, Strombom P et al (2018) Adoption of total neoadjuvant therapy for locally advanced rectal cancer. JAMA Oncol 4:e180071. https:\/\/doi.org\/10.1001\/jamaoncol.2018.0071","journal-title":"JAMA Oncol"},{"key":"5044_CR8","doi-asserted-by":"publisher","first-page":"3212","DOI":"10.1200\/JCO.19.00308","volume":"37","author":"E Fokas","year":"2019","unstructured":"Fokas E, Allg\u00e4uer M, Polat B et al (2019) Randomized phase II trial of chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: CAO\/ARO\/AIO-12. J Clin Oncol 37:3212\u20133222. https:\/\/doi.org\/10.1200\/JCO.19.00308","journal-title":"J Clin Oncol"},{"key":"5044_CR9","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/NEJMoa2303269","volume":"389","author":"D Schrag","year":"2023","unstructured":"Schrag D, Shi Q, Weiser MR et al (2023) Preoperative treatment of locally advanced rectal cancer. N Engl J Med 389:322\u2013334. https:\/\/doi.org\/10.1056\/NEJMoa2303269","journal-title":"N Engl J Med"},{"key":"5044_CR10","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/s1470-2045(20)30555-6","volume":"22","author":"RR Bahadoer","year":"2021","unstructured":"Bahadoer RR, Dijkstra EA, van Etten B et al (2021) Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol 22:29\u201342. https:\/\/doi.org\/10.1016\/s1470-2045(20)30555-6","journal-title":"Lancet Oncol"},{"key":"5044_CR11","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/S1470-2045(21)00079-6","volume":"22","author":"T Conroy","year":"2021","unstructured":"Conroy T, Bosset JF, Etienne PL et al (2021) Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 22:702\u2013715. https:\/\/doi.org\/10.1016\/S1470-2045(21)00079-6","journal-title":"Lancet Oncol"},{"key":"5044_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.suronc.2022.101739","volume":"43","author":"MC Fernandes","year":"2022","unstructured":"Fernandes MC, Gollub MJ, Brown G (2022) The importance of MRI for rectal cancer evaluation. Surg Oncol 43:101739. https:\/\/doi.org\/10.1016\/j.suronc.2022.101739","journal-title":"Surg Oncol"},{"key":"5044_CR13","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1007\/s00261-022-03495-4","volume":"47","author":"E Altinmakas","year":"2022","unstructured":"Altinmakas E, Dogan H, Taskin OC et al (2022) Extramural venous invasion (EMVI) revisited: a detailed analysis of various characteristics of EMVI and their role as a predictive imaging biomarker in the neoadjuvant treatment response in rectal cancer. Abdom Radiol 47:1975\u20131987. https:\/\/doi.org\/10.1007\/s00261-022-03495-4","journal-title":"Abdom Radiol"},{"key":"5044_CR14","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/s0140-6736(00)04040-x","volume":"357","author":"RG Beets-Tan","year":"2001","unstructured":"Beets-Tan RG, Beets GL, Vliegen RF et al (2001) Accuracy of magnetic resonance imaging in prediction of tumour-free resection margin in rectal cancer surgery. Lancet 357:497\u2013504. https:\/\/doi.org\/10.1016\/s0140-6736(00)04040-x","journal-title":"Lancet"},{"key":"5044_CR15","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.canep.2018.01.009","volume":"53","author":"KM Augestad","year":"2018","unstructured":"Augestad KM, Keller DS, Bakaki PM et al (2018) The impact of rectal cancer tumor height on recurrence rates and metastatic location: a competing risk analysis of a national database. Cancer Epidemiol 53:56\u201364. https:\/\/doi.org\/10.1016\/j.canep.2018.01.009","journal-title":"Cancer Epidemiol"},{"key":"5044_CR16","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.ijrobp.2021.06.013","volume":"111","author":"DP Schaap","year":"2021","unstructured":"Schaap DP, Voogt ELK, Burger JWA et al (2021) Prognostic implications of MRI-detected EMVI and tumor deposits and their response to neoadjuvant therapy in cT3 and cT4 rectal cancer. Int J Radiat Oncol Biol Phys 111:816\u2013825. https:\/\/doi.org\/10.1016\/j.ijrobp.2021.06.013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5044_CR17","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/bjc.2013.603","volume":"110","author":"M Chand","year":"2014","unstructured":"Chand M, Swift RI, Tekkis PP, Chau I, Brown G (2014) Extramural venous invasion is a potential imaging predictive biomarker of neoadjuvant treatment in rectal cancer. Br J Cancer 110:19\u201325. https:\/\/doi.org\/10.1038\/bjc.2013.603","journal-title":"Br J Cancer"},{"key":"5044_CR18","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.bulcan.2022.03.003","volume":"109","author":"A Mayaud","year":"2022","unstructured":"Mayaud A, Bousarsar A, Soltani S et al (2022) Prognostic factors of pelvic MRI at the initial workflow in locally advanced rectal cancer: focus on extra mural venous invasion and tumour deposits. Bull Cancer 109:1269\u20131276. https:\/\/doi.org\/10.1016\/j.bulcan.2022.03.003","journal-title":"Bull Cancer"},{"key":"5044_CR19","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/codi.16032","volume":"24","author":"A Chandramohan","year":"2022","unstructured":"Chandramohan A, Mittal R, Dsouza R et al (2022) Prognostic significance of MR identified EMVI, tumour deposits, mesorectal nodes and pelvic side wall disease in locally advanced rectal cancer. Colorectal Dis 24:428\u2013438. https:\/\/doi.org\/10.1111\/codi.16032","journal-title":"Colorectal Dis"},{"key":"5044_CR20","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1038\/s41416-023-02384-x","volume":"129","author":"M Zhao","year":"2023","unstructured":"Zhao M, Feng L, Zhao K et al (2023) An MRI-based scoring system for pretreatment risk stratification in locally advanced rectal cancer. Br J Cancer 129:1095\u20131104. https:\/\/doi.org\/10.1038\/s41416-023-02384-x","journal-title":"Br J Cancer"},{"issue":"Suppl 1","key":"5044_CR21","doi-asserted-by":"publisher","first-page":"S164","DOI":"10.1016\/j.acra.2023.05.031","volume":"30","author":"R Zhao","year":"2023","unstructured":"Zhao R, Zhao W, Zhu Y et al (2023) Implication of MRI risk stratification system on the survival benefits of adjuvant chemotherapy after neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer. Acad Radiol 30(Suppl 1):S164-s175. https:\/\/doi.org\/10.1016\/j.acra.2023.05.031","journal-title":"Acad Radiol"},{"key":"5044_CR22","doi-asserted-by":"publisher","unstructured":"(2006) Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study. BMJ 333:779. https:\/\/doi.org\/10.1136\/bmj.38937.646400.55","DOI":"10.1136\/bmj.38937.646400.55"},{"key":"5044_CR23","doi-asserted-by":"publisher","first-page":"3724","DOI":"10.1200\/JCO.23.00903","volume":"41","author":"E Basch","year":"2023","unstructured":"Basch E, Dueck AC, Mitchell SA et al (2023) Patient-reported outcomes during and after treatment for locally advanced rectal cancer in the PROSPECT trial (Alliance N1048). J Clin Oncol 41:3724\u20133734. https:\/\/doi.org\/10.1200\/JCO.23.00903","journal-title":"J Clin Oncol"},{"key":"5044_CR24","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1200\/JCO.2011.39.6036","volume":"30","author":"A Dewdney","year":"2012","unstructured":"Dewdney A, Cunningham D, Tabernero J et al (2012) Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). J Clin Oncol 30:1620\u20131627. https:\/\/doi.org\/10.1200\/JCO.2011.39.6036","journal-title":"J Clin Oncol"},{"key":"5044_CR25","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S1470-2045(09)70381-X","volume":"11","author":"YJ Chua","year":"2010","unstructured":"Chua YJ, Barbachano Y, Cunningham D et al (2010) Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial. Lancet Oncol 11:241\u2013248. https:\/\/doi.org\/10.1016\/S1470-2045(09)70381-X","journal-title":"Lancet Oncol"},{"key":"5044_CR26","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1002\/jmri.21742","volume":"29","author":"SH Kim","year":"2009","unstructured":"Kim SH, Lee JM, Park HS, Eun HW, Han JK, Choi BI (2009) Accuracy of MRI for predicting the circumferential resection margin, mesorectal fascia invasion, and tumor response to neoadjuvant chemoradiotherapy for locally advanced rectal cancer. J Magn Reson Imaging 29:1093\u20131101. https:\/\/doi.org\/10.1002\/jmri.21742","journal-title":"J Magn Reson Imaging"},{"key":"5044_CR27","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1111\/j.1463-1318.2007.01451.x","volume":"86","author":"JB Jiang","year":"2006","unstructured":"Jiang JB, Dai Y, Zhang XM et al (2006) Accuracy of preoperative magnetic resonance imaging in prediction of pathological stage and circumferential resection margin in rectal cancer. Zhonghua Yi Xue Za Zhi 86:961\u2013964. https:\/\/doi.org\/10.1111\/j.1463-1318.2007.01451.x","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"5044_CR28","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/bjs.4034","volume":"90","author":"G Brown","year":"2003","unstructured":"Brown G, Radcliffe AG, Newcombe RG, Dallimore NS, Bourne MW, Williams GT (2003) Preoperative assessment of prognostic factors in rectal cancer using high-resolution magnetic resonance imaging. Br J Surg 90:355\u2013364. https:\/\/doi.org\/10.1002\/bjs.4034","journal-title":"Br J Surg"},{"key":"5044_CR29","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1007\/s00384-020-03632-9","volume":"35","author":"JJ van den Broek","year":"2020","unstructured":"van den Broek JJ, van der Wolf FSW, Heijnen LA, Schreurs WH (2020) The prognostic importance of MRI detected extramural venous invasion (mrEMVI) in locally advanced rectal cancer. Int J Colorectal Dis 35:1849\u20131854. https:\/\/doi.org\/10.1007\/s00384-020-03632-9","journal-title":"Int J Colorectal Dis"},{"key":"5044_CR30","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1002\/bjs.11233","volume":"106","author":"S Nougaret","year":"2019","unstructured":"Nougaret S, Castan F, de Forges H et al (2019) Early MRI predictors of disease-free survival in locally advanced rectal cancer from the GRECCAR 4 trial. Br J Surg 106:1530\u20131541. https:\/\/doi.org\/10.1002\/bjs.11233","journal-title":"Br J Surg"},{"key":"5044_CR31","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/s0140-6736(94)92206-3","volume":"344","author":"IJ Adam","year":"1994","unstructured":"Adam IJ, Mohamdee MO, Martin IG et al (1994) Role of circumferential margin involvement in the local recurrence of rectal cancer. Lancet 344:707\u2013711. https:\/\/doi.org\/10.1016\/s0140-6736(94)92206-3","journal-title":"Lancet"},{"key":"5044_CR32","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1097\/SLA.0000000000001193","volume":"263","author":"NJ Battersby","year":"2016","unstructured":"Battersby NJ, How P, Moran B et al (2016) Prospective validation of a low rectal cancer magnetic resonance imaging staging system and development of a local recurrence risk stratification model: the MERCURY II study. Ann Surg 263:751\u2013760. https:\/\/doi.org\/10.1097\/SLA.0000000000001193","journal-title":"Ann Surg"},{"key":"5044_CR33","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1200\/JCO.2012.45.3258","volume":"32","author":"FG Taylor","year":"2014","unstructured":"Taylor FG, Quirke P, Heald RJ et al (2014) Preoperative magnetic resonance imaging assessment of circumferential resection margin predicts disease-free survival and local recurrence: 5-year follow-up results of the MERCURY study. J Clin Oncol 32:34\u201343. https:\/\/doi.org\/10.1200\/JCO.2012.45.3258","journal-title":"J Clin Oncol"},{"key":"5044_CR34","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.232838","volume":"314","author":"S Nougaret","year":"2025","unstructured":"Nougaret S, Gormly K, Lambregts DMJ et al (2025) MRI of the rectum: a decade into DISTANCE, moving to DISTANCED. Radiology 314:e232838. https:\/\/doi.org\/10.1148\/radiol.232838","journal-title":"Radiology"},{"key":"5044_CR35","doi-asserted-by":"publisher","first-page":"e1555","DOI":"10.1002\/onco.13824","volume":"26","author":"S Liu","year":"2021","unstructured":"Liu S, Jiang T, Xiao L et al (2021) Total neoadjuvant therapy (TNT) versus standard neoadjuvant chemoradiotherapy for locally advanced rectal cancer: a systematic review and meta-analysis. Oncologist 26:e1555\u2013e1566. https:\/\/doi.org\/10.1002\/onco.13824","journal-title":"Oncologist"},{"key":"5044_CR36","doi-asserted-by":"publisher","first-page":"e766","DOI":"10.1097\/SLA.0000000000005799","volume":"278","author":"EA Dijkstra","year":"2023","unstructured":"Dijkstra EA, Nilsson PJ, Hospers GAP et al (2023) Locoregional failure during and after short-course radiotherapy followed by chemotherapy and surgery compared with long-course chemoradiotherapy and surgery: a 5-year follow-up of the RAPIDO trial. Ann Surg 278:e766\u2013e772. https:\/\/doi.org\/10.1097\/SLA.0000000000005799","journal-title":"Ann Surg"},{"key":"5044_CR37","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.annonc.2024.06.019","volume":"35","author":"T Conroy","year":"2024","unstructured":"Conroy T, Castan F, Etienne PL et al (2024) Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial. Ann Oncol 35:873\u2013881. https:\/\/doi.org\/10.1016\/j.annonc.2024.06.019","journal-title":"Ann Oncol"},{"key":"5044_CR38","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","volume":"386","author":"A Cercek","year":"2022","unstructured":"Cercek A, Lumish M, Sinopoli J et al (2022) PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med 386:2363\u20132376. https:\/\/doi.org\/10.1056\/NEJMoa2201445","journal-title":"N Engl J Med"},{"key":"5044_CR39","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/S1470-2045(11)70097-3","volume":"12","author":"W van Gijn","year":"2011","unstructured":"van Gijn W, Marijnen CA, Nagtegaal ID et al (2011) Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol 12:575\u2013582. https:\/\/doi.org\/10.1016\/S1470-2045(11)70097-3","journal-title":"Lancet Oncol"}],"container-title":["International Journal of Colorectal Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00384-025-05044-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00384-025-05044-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00384-025-05044-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:53:15Z","timestamp":1764723195000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00384-025-05044-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,2]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5044"],"URL":"https:\/\/doi.org\/10.1007\/s00384-025-05044-z","relation":{},"ISSN":["1432-1262"],"issn-type":[{"value":"1432-1262","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,2]]},"assertion":[{"value":"13 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Institutional Review Board approval was obtained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"244"}}